首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1408981

全球糖尿病視網膜病變市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 131 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球糖尿病視網膜病變市場的市場規模將從 2022 年的 86.1 億美元達到近 150.8 億美元，2023-2030 年研究期間CAGR為 7.26%。

糖尿病視網膜病變是一種與糖尿病相關的眼部疾病，會影響視網膜（眼睛後部的感光組織）。它是糖尿病患者視力障礙的一個主要原因。隨著與糖尿病相關的血糖水平升高對視網膜內的小血管造成損害，這種情況逐漸發展。

市場動態

糖尿病視網膜病變市場由幾個關鍵因素驅動，其中全球糖尿病盛行率不斷上升是主要原因。由於糖尿病仍然是一個重大的健康問題，發病率的上升導致越來越多的人面臨糖尿病視網膜病變的風險，從而推動了對診斷和治療解決方案的需求。診斷工具和影像技術的技術進步對增強早期檢測能力的貢獻顯而易見。對定期眼部篩檢的重視以及將遠距醫療涵蓋篩檢計畫進一步擴大了可近性，特別是在服務不足的地區。藥物創新，包括玻璃體內注射和針對糖尿病黃斑水腫的藥物，透過提供有效的管理選擇，促進市場的發展。醫療保健專業人員和患者對眼睛健康在糖尿病管理中的重要性的認知不斷提高，鼓勵增加篩檢和早期介入。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球糖尿病視網膜病變市場的各個細分市場進行了包容性評估。糖尿病視網膜病變產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲糖尿病視網膜病變市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。糖尿病視網膜病變市場的主要參與者包括拜耳公司、艾伯維公司、諾華公司、Oxurion NV、Sirnaomics、Alimera Sciences、Ampio Pharmaceuticals Inc.、BCNPeptides、Kowa Company Ltd.和Genentech, Inc.。查看競爭格局，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：糖尿病視網膜病變公司的競爭格局

糖尿病視網膜病變市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Bayer AG

公司簡介
公司收入
產品
最近的發展

ABBVIE INC.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Oxurion NV

公司簡介
公司收入
產品
最近的發展

Sirnaomics

公司簡介
公司收入
產品
最近的發展

Alimera Sciences

公司簡介
公司收入
產品
最近的發展

Ampio Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

BCNPeptides

公司簡介
公司收入
產品
最近的發展

Kowa Company Ltd.

公司簡介
公司收入
產品
最近的發展

Genentech Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113274

The global demand for Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.08 BN by 2030 from USD 8.61 BN in 2022 with a CAGR of 7.26% under the study period 2023 - 2030.

Diabetic retinopathy is an eye disease linked to diabetes, impacting the retina-the light-sensitive tissue at the back of the eye. It stands as a prominent cause of vision impairment among individuals with diabetes. The condition develops gradually as elevated levels of blood sugar associated with diabetes cause damage to the small blood vessels within the retina.

MARKET DYNAMICS

The diabetic retinopathy market is driven by several key factors, with the increasing global prevalence of diabetes being a primary contributor. As diabetes remains a significant health concern, the rising incidence contributes to a growing population at risk of diabetic retinopathy, propelling the demand for diagnostic and treatment solutions. The pivotal role of technological advancements in diagnostic tools and imaging techniques is evident in their contribution to enhancing early detection capabilities. The emphasis on regular eye screenings and the integration of telemedicine in screening programs further expands accessibility, particularly in underserved areas. Pharmaceutical innovations, including intravitreal injections and medications targeting diabetic macular edema, contribute to the market's development by offering effective management options. The heightened awareness among healthcare professionals and patients about the importance of eye health in diabetes management encourages increased screenings and early intervention.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic retinopathy. The growth and trends of diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Proliferative Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy

By Management

Anti-VEGF
Intraocular Steroid Injection
Laser Surgery
Vitrectomy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Diabetic Retinopathy market include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., and Genentech, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Management
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions
5.5 Non-proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions

6 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY MANAGEMENT

6.1 Overview by Management
6.2 Historical and Forecast Data
6.3 Analysis by Management
6.4 Anti-VEGF Historic and Forecast Sales by Regions
6.5 Intraocular Steroid Injection Historic and Forecast Sales by Regions
6.6 Laser Surgery Historic and Forecast Sales by Regions
6.7 Vitrectomy Historic and Forecast Sales by Regions

7 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DIABETIC RETINOPATHY COMPANIES

8.1. Diabetic Retinopathy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF DIABETIC RETINOPATHY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. ABBVIE INC.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Oxurion NV
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Sirnaomics
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Alimera Sciences
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Ampio Pharmaceuticals Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. BCNPeptides
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Kowa Company Ltd.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Genentech Inc.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments